4//SEC Filing
CoLucid Pharmaceuticals, Inc. 4
Accession 0000911916-16-000693
CIK 0001348649operating
Filed
Nov 30, 7:00 PM ET
Accepted
Dec 1, 4:43 PM ET
Size
5.5 KB
Accession
0000911916-16-000693
Insider Transaction Report
Form 4
Dallas Matthew D
Chief Financial Officer
Transactions
- Sale
Common Stock
2016-12-01$35.17/sh−1,473$51,801→ 41,601 total
Footnotes (3)
- [F1]Securities sold pursuant to a written plan intended to comply with Rule 10b5-1(c)(i) adopted by Mr. Dallas on August 15, 2016. One purpose of the plan is to sell shares of common stock acquired under the CoLucid Pharmaceuticals, Inc. Employee Stock Purchase Plan.
- [F2]Represents the sale of 1,473 shares in multiple transactions, ranging in price from $35.00 to $35.45 per share, resulting in a weighted average sale price of $35.1671. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each price within the range.
- [F3]Includes 5,574 shares acquired under the CoLucid Pharmaceuticals, Inc. Employee Stock Purchase Plan through November 30, 2016.
Documents
Issuer
CoLucid Pharmaceuticals, Inc.
CIK 0001348649
Entity typeoperating
Related Parties
1- filerCIK 0001348649
Filing Metadata
- Form type
- 4
- Filed
- Nov 30, 7:00 PM ET
- Accepted
- Dec 1, 4:43 PM ET
- Size
- 5.5 KB